Back to search
FDAFDA · Food and drugs·Recall number D-0249-2026

Dexamethasone Moxifloxacin, 1 mg/mL and 5 mg/mL, 1 mL Intraocular Injection, Rx only, Imprimis NJOF, LLC, Ledgewood, NJ 07852, NDC 71384-512-0.1

Published January 14, 2026 · Recall initiated: December 18, 2025

Summary

FDA records drug Class II recall D-0249-2026, published January 14, 2026 and initiated December 18, 2025. Recalling firm: Imprimis NJOF, LLC; Status: Ongoing; Reported quantity: 778 boxes of 15,540 pre-filled syringes; Lot: Lot: 25MAY051, Expires: 06/26/2026; 25AUG003, Expires:08/07/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of particulate matter - Glass like particles.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Imprimis NJOF, LLC
Distributor
U.S Nationwide
Lot
Lot: 25MAY051, Expires: 06/26/2026; 25AUG003, Expires:08/07/2026
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Dexamethasone Moxifloxacin, 1 mg/mL and 5 mg/mL, 1 mL Intraocular Injection, Rx only, Imprimis NJOF, LLC, Ledgewood, NJ 07852, NDC 71384-512-0.1 recalled?

Yes. FDA published recall D-0249-2026 on January 14, 2026. Reported hazard: Presence of particulate matter - Glass like particles.

What should I do if I have this product?

Voluntary: Firm initiated · Letter